Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
HPV vaccines: when one plus one equals three.
Journal: The Lancet. Global health
Published: August 03, 2022
Gaps and Opportunities to Improve Prevention of Human Papillomavirus-Related Cancers.
Journal: Journal of women's health (2002)
Published: December 06, 2021
A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3).
Journal: Gynecologic oncology
Published: November 21, 2019
Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy.
Journal: Therapeutic advances in vaccines
Published: May 15, 2017
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Journal: Lancet (London, England)
Published: September 21, 2015
HPV Infection-Associated Cancers: Next-Generation Technology for Diagnosis and Treatment.
Journal: Cancer immunology research
Published: October 05, 2014
Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: November 02, 2010
Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3.
Journal: Cancer immunology, immunotherapy : CII
Published: September 22, 2009
Last Updated: 09/26/2026